Date: 2018-07-24
Type of information: Nomination
Compound: vie-president
Company: MorphoSys (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 24, 2018, MorphoSys announced the appointment of Jennifer L. Herron as President of MorphoSys US Inc. and Executive Vice President, Global Commercial, effective July 23, 2018. Ms. Herron was also appointed as member of the board of directors of MorphoSys US Inc. In this newly created role, Ms. Herron will lead the build of MorphoSys's U.S. subsidiary with a focus on establishing the company's commercial capabilities in the U.S. While the MorphoSys corporate headquarters will remain in Planegg near Munich, Germany, the MorphoSys US operations, which will be located in New Jersey, will establish a strong U.S. footprint in preparation for the planned commercialization of MOR208.
- Ms. Herron built her career in leadership positions in commercial, marketing and general management in the global pharmaceutical industry over the last 27 years. She joins MorphoSys after her previous role as Executive Vice President and Chief Commercial Officer at Ariad Pharmaceuticals (today: Takeda), where she was responsible for the commercial vision, strategy, operating model and execution worldwide to include Iclusig®(ponatinib) commercialization, launch readiness for Alunbrig®) (brigatinib) and ultimately the transition of the commercial organization to Takeda as part of the acquisition. Before that, she worked ten years for BMS, where she served in various roles of increasing leadership responsibility including the turnaround of the Orencia® business as Vice President US Immunology; and the launch of the Immuno Oncology portfolio as General Manager, Puerto Rico and the Caribbean. Prior to joining BMS, Ms. Herron worked in various marketing roles in oncology for Novartis Oncology and SmithKline Beecham Oncology (today: GSK). Ms. Herron started her career as a clinical research associate at Boehringer Mannheim Pharmaceuticals (today: Roche). Ms. Herron earned a Bachelor of Arts in Biology and Economics from Lehigh University, Pennsylvania, and an MBA from Georgetown University, Washington D.C.
Financial terms:
Latest news:
Is general: Yes
